

# BioCentury - Bio€quity Europe 2018

MONDAY, MAY 14, 2018

## BIO GLOBALIZATION HITS HOME - IS EUROPE CAUGHT IN THE MIDDLE?

Over nearly two decades, *Bio€quity Europe* has debated Europe's relationship to the U.S. on scientific achievement, corporate leadership and access to capital. In 2018, *Bio€quity Europe* turns to the East, challenging both biotech innovators and investors to face the consequences of a fast-rising Asia on one side and the continuing leadership set by U.S. on the other.

5:30 PM TO 5:45 PM

## BIO€QUITY EUROPE ORGANIZERS WELCOME

### CITY HALL / PACIFICATIEZAAL

- Mathias De Clercq, Senior Deputy Mayor and Deputy Mayor of the Port, Economy and Enterprise, City of Ghent
- David Flores, President & CEO, BioCentury
- Christophe Peeters, Vice Mayor, Retail, Festivities, Finance and Innovation, City of Ghent
- Pam Putz, Managing Director, EBD Group
- David Thomas, Senior Director, Industry Research and Policy Analysis at Biotechnology Innovation Organization

5:45 PM TO 7:00 PM

## OPENING SESSION - FIRESIDE CHAT WITH BELGIAN PATHFINDERS ON RESILIENCE AND BUILDING GLOBAL VALUE

### CITY HALL / PACIFICATIEZAAL

Belgium has provided Europe with a host of pioneering biotechs, led by CEOs who have demonstrated resilience and stamina in the pursuit of homegrown innovation. What have these pathfinders learned, and how do these lessons apply as bio globalization hits home?

Moderator: Karen Bernstein Ph.D, Chairman, BioCentury, Inc.

- Rudy Dekeyser, Ph.D, Managing Partner of LSP's Health Economics Fund
- Edwin Moses Ph.D., CEO, Ablynx

- Onno van de Stolpe, CEO, Galapagos

7:00 PM TO 8:30 PM

WELCOME RECEPTION

CITY HALL, GHENT

TUESDAY, MAY 15, 2018

8:00 AM

BIO€QUITY EUROPE REGISTRATION OPENS

8:50 AM TO 9:00 PM

BIO€QUITY EUROPE OPENS WITH EURONEXT BELL RINGING CEREMONY

LEVEL 2, ZAAL RECTOR VERMEYLEN

- Anna Chrisman, Group Managing Director, EBD Group
- David Flores, President & CEO, BioCentury
- Vincent Van Dessel, CEO and Chairman Euronext Brussels
- Dirk Reyn, Vice Chairman, flanders.bio

9:00 AM TO 9:15 AM

WELCOMING THOUGHTS: EUROPE LOOKS EAST AND WEST

LEVEL 2, ZAAL RECTOR VERMEYLEN

9:15 AM TO 10:15 AM

PLENARY 1 - BIO GLOBALIZATION HITS HOME: HOW SHOULD EUROPE RESPOND?

LEVEL 2, ZAAL RECTOR VERMEYLEN

Asia's rush into biotech provides new opportunity, new capital – and competition – for European innovators who have been focused on the U.S. What should European life science leaders be thinking about Asia's commitment to invigorate life sciences innovation, prioritize regulatory modernization and build a high-energy startup ecosystem?

Moderator: Josh Berlin, Executive Director, New Ventures, BioCentury

- Roel Bulthuis, Head, M Ventures
- Franck Le Deu, Senior Partner & Head of Greater China Healthcare Practice, McKinsey
- Nanna Lüneborg Ph.D., Partner, Novo Ventures
- Jörg Neermann Ph.D, Partner, LSP
- Antoine Papiernik, Chairman & Managing Partner, Sofinnova

- Patrick van Beneden, Partner, Healthcare, Gimv

10:15 AM TO 11:15 AM

PLENARY 2 - BIO GLOBALIZATION HITS HOME: WHERE CAN EUROPE LEAD IN STRATEGIC R&D?

LEVEL 2, ZAAL RECTOR VERMEYLEN

Where is European science and biotech going to lead as genomics and regenerative medicine gather steam globally?

Moderator: C. Simone Fishburn Ph.D., Vice President & Executive Editor, BioCentury

- Joanne Hackett Ph.D, CCO, Genomics England
- Tim Haines, Managing Partner, Abingworth
- Bernd Stowasser Ph.D., Head Global Public Private Partnerships and R&D Alliance Management, Sanofi
- Mirko Scherer, Ph.D., Managing Partner, TVM Capital China
- John Tchelingirian, Ph.D., CEO, Promethera
- Nathalie ter Wengel M.D., European Head External Science and Innovation, Pfizer

11:00 AM TO 11:10 AM

CARDIOR PHARMACEUTIC CLAS GMBH

LEVEL 1, RECTOR GILLIS

[View company profile](#)

11:00 AM TO 11:20 AM

MC2 THERAPEUTICS A/S

LEVEL 1+, PRIORZAAL

[View company profile](#)

11:10 AM TO 11:20 AM

AELIN THERAPEUTICS

LEVEL 1, RECTOR GILLIS

[View company profile](#)

11:20 AM TO 11:30 AM

ATRIVA THERAPEUTICS GMBH

LEVEL 1, RECTOR GILLIS

[View company profile](#)

11:20 AM TO 11:40 AM

ACESION PHARMA APS

LEVEL 1+, PRIORZAAL

[View company profile](#)

11:30 AM TO 12:30 PM

BIOTECH CEO WORKSHOP 8.0: WHAT EUROPEAN CEOS NEED TO KNOW TO ATTRACT U.S. CAPITAL

LEVEL 2, ZAAL RECTOR VERMEYLEN

What do U.S. VCs need to see in order to put money into European Start Ups? This panel of VCs and executives debate what's need to overcome 'gating' factors for U.S. investment in Europe

- Carole Nuechterlein, Partner, Roche Venture Fund
- Florian Fischer, CFO, Affimed N.V.
- Chris Hollowood, Ph.D., Chief Investment Officer and a Managing Partner, Syncona Investment Management
- Ravi Mehrotra Ph.D., Partner, MTS Health Partners
- Bibhash Mukhopadhyay Ph.D., Principal, NEA
- Henrijette Richter Ph.D., Managing Partner, Sofinnova Partners

11:30 AM TO 11:40 AM

GLYCOSTEM THERAPEUTICS

LEVEL 1, RECTOR GILLIS

[View company profile](#)

11:40 AM TO 11:50 AM

MINORYX THERAPEUTICS S.L.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

11:40 AM TO 12:00 PM

VAXIMM AG

LEVEL 1+, PRIORZAAL

[View company profile](#)

11:50 AM TO 12:00 PM

TUSK THERAPEUTICS LTD.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

12:00 PM TO 2:00 PM

LUNCH AND NETWORKING TIME

LEVEL 0, KAPITELZAAL AND LEVEL 1

12:00 PM TO 12:10 PM

HEPAREGENIX GMBH

LEVEL 1, RECTOR GILLIS

[View company profile](#)

12:00 PM TO 12:20 PM

NEWRON PHARMACEUTICALS S.P.A. (SIX:NWRN)

LEVEL 1+, PRIORZAAL

[View company profile](#)

12:10 PM TO 12:20 PM

ARTIOS PHARMA LTD.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

12:20 PM TO 12:40 PM

NOUSCOM AG

LEVEL 1+, PRIORZAAL

[View company profile](#)

12:20 PM TO 12:30 PM

NOVINTUM BIOSCIENCE LTD.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

2:00 PM TO 3:10 PM

WHAT ARE CHINESE INVESTORS LOOKING FOR IN EUROPEAN ASSETS?

ROOM: LEVEL 2+, OUDE INFIRMERIE

Inaugural China-Europe Showcase (Hosted by BioCentury and BayHelix)

Flush with cash and driven by government reforms to invigorate life sciences innovation, Chinese VCs and corporate strategics are hunting for assets in Europe. These top investors explain how European biotechs can position themselves to take advantage of new financing opportunities from China.

Co-Moderators:

- David Flores, President and CEO, BioCentury
- Kewen JIN, M.D., Managing Director, Serica Capital

Speakers:

- Sean Cao, Ph.D., Managing Director, C-Bridge Capital
- Leon Chen, Ph.D., CEO, 6 Dimensions Capital
- Ting JIA "TJ", Ph.D., Managing Director, Hillhouse Capital Management
- Yuwen LIU, Founding Partner, Bohe Angel Fund
- Huaizheng PENG, M.D., Ph.D., Managing Director, CMS Medical Venture Investment Ltd.

2:00 PM TO 2:10 PM

HORAMA S.A.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

2:00 PM TO 2:20 PM

CELL MEDICA LTD.

LEVEL 1+, PRIORZAAL

[View company profile](#)

2:10 PM TO 2:20 PM

IMCYSE S.A.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

2:20 PM TO 2:30 PM

IMMUNE BIOSOLUTIONS INC.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

2:20 PM TO 2:40 PM

IO BIOTECH APS

LEVEL 1+, PRIORZAAL

[View company profile](#)

2:30 PM TO 3:30 PM

IS EUROPE READY FOR GROWTH CAPITAL FUNDS?

LEVEL 2, ZAAL RECTOR VERMEYLEN

To reach bellwether status, European biotechs need capital to grow beyond clinical proof of concept. But the dearth of specialist growth capital forces European innovators to look to the US, and increasingly toward pools of Asian money looking for commercial opportunities. Is it time for European funds to provide a homegrown solution, or cede the space to offshore money? Or does geography for growth capital matter less than early stage investments?

Moderator: Paul Hadden, Partner, HealthCare Royalty Partners

- Alain Baetens, Head of Listings, Belgium, Euronext
- Chris De Jonghe Ph.D, Head of Life Sciences & Care, Group Manager Venture Capital, PMV
- Michele Ollier, M.D., Partner, Medicxi
- Gilles Nobécourt, Partner, Andera Partners
- Greg Parekh Ph.D, Partner, New Rhein Healthcare Investors
- Graziano Seghezzi, Managing Partner, Sofinnova Partners
- Thomas Stockman, Managing Director, Healthcare, RBC Capital Markets

2:30 PM TO 2:40 PM

INTHERA BIOSCIENCE AG

LEVEL 1, RECTOR GILLIS

[View company profile](#)

2:40 PM TO 2:50 PM

APTEEUS S.A.R.L.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

2:50 PM TO 3:00 PM

DUCENTIS BIOTHERAPEUTICS LTD.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

3:00 PM TO 3:10 PM

CAMEL-IDS N.V.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

3:00 PM TO 3:20 PM

PROMETHERA BIOSCIENCES S.A.

LEVEL 1+, PRIORZAAL



[View company profile](#)

3:10 PM TO 3:20 PM

MEDHERANT LTD.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

3:15 PM TO 4:30 PM

CHINA CASE STUDIES: LESSONS LEARNED FROM EUROPEAN DEALS

ROOM: LEVEL 2+, OUDE INFIRMERIE

Inaugural China-Europe Showcase (Hosted by BioCentury and BayHelix)

This case study session dissects the drivers of the Chinese attraction to Europe, and how European biotech need to approach these new opportunities.

Moderator: Jorge Santos da Silva Ph.D., Partner, McKinsey & Co.

- Bianca Ahrens, Ph.D., Scientific Director, Business Development & Portfolio Management, MorphoSys AG
- Stephan Lensky, Ph.D., COO/CBO, EpiMab Biotherapeutics Inc.
- Ji LI, Ph.D., Global Head of Business Development, BeiGene Ltd.
- Mai-Jing LIAO, Ph.D., SVP, Head of Business Development and Portfolio Management, Harbour BioMed
- Donald Wyatt, VP of Business Development & Alliance Management, 3SBio Inc.

3:20 PM TO 3:30 PM

MOLECULAR TARGETED RADIOPHARMACEUTICALS SA

LEVEL 1, RECTOR GILLIS

[View company profile](#)

3:20 PM TO 3:40 PM

NBE-THERAPEUTICS AG

LEVEL 1+, PRIORZAAL

[View company profile](#)

ONCODNA S.A.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

3:40 PM TO 3:50 PM

IPROTEOS S.L.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

3:40 PM TO 4:00 PM

ADDEX THERAPEUTICS LTD.

LEVEL 1+, PRIORZAAL

[View company profile](#)

3:45 PM TO 5:15 PM

PRE-SEED SHOWCASE 1

LEVEL 2, ZAAL RECTOR VERMEYLEN

Selected Pre-Seed Companies present to a diverse panel of Bio€quity Europe 'judges' who provide high level feedback on their business plan, presentation and overall strategy.

Moderator: Eric Pierce, Publisher, BioCentury

Judges:

- Karen Bernstein Ph.D., Chairman, BioCentury
- Alicia Irurzun-Lafitte, Principal, M Ventures
- JR Rothe Ph.D, Managing Partner, LSP
- Nico Vandervelpen, Managing Director Bioqube Ventures

Pre-Seed Companies:

- Inositec AG (15:45)
- Proteodesign (16:00)
- TolerogenixX (16:15)
- Proteinlogic (16:30)
- NeoPhore Ltd. (16:45)

- Draupnir Bio (17:00)

3:50 PM TO 4:00 PM

PDC\*LINE PHARMA

LEVEL 1, RECTOR GILLIS

[View company profile](#)

4:00 PM TO 4:10 PM

TOPAS THERAPEUTICS GMBH

LEVEL 1, RECTOR GILLIS

[View company profile](#)

4:00 PM TO 4:20 PM

BERGENBIO ASA (OSLO: BGBIO)

LEVEL 1+, PRIORZAAL

[View company profile](#)

4:10 PM TO 4:20 PM

NOVADISCOVERY

LEVEL 1, RECTOR GILLIS

[View company profile](#)

4:20 PM TO 4:30 PM

STEP PHARMA S.A.S.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

4:20 PM TO 4:40 PM

ACTINIUM PHARMACEUTICALS INC.

LEVEL 1+, PRIORZAAL

[View company profile](#)

4:30 PM TO 4:40 PM

EVOX THERAPEUTICS LTD.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

4:40 PM TO 5:00 PM

ETHERNA IMMUNOTHERAPIES N.V.

LEVEL 1+, PRIORZAAL

[View company profile](#)

4:40 PM TO 4:50 PM

XBRANE BIOPHARMA AB

LEVEL 1, RECTOR GILLIS

[View company profile](#)

4:50 PM TO 5:00 PM

HIL APPLIED MEDICAL

LEVEL 1, RECTOR GILLIS

[View company profile](#)

5:00 PM TO 5:20 PM

THROMBOGENICS  
N.V. (EURONEXT  
BRUSSELS:THR)

LEVEL 1+,  
PRIORZAAL

[View company profile](#)

CUREVAC AG

LEVEL 2+, OUDE  
INFIRMERIE

[View company profile](#)

FORENDO PHARMA  
OY

LEVEL 1, RECTOR  
GILLIS

[View company profile](#)

5:20 PM TO 5:40 PM

REAPPLIX APS

VERONA PHARMA  
PLC (LSE:VRP;

GENKYOTEX S.A.  
(EURONEXT:GKTX)

	LEVEL 1, RECTOR GILLIS <a href="#">View company profile</a>	NASDAQ:VRNA) LEVEL 1+, PRIORZAAL <a href="#">View company profile</a>	LEVEL 2+, OUDE INFIRMERIE <a href="#">View company profile</a>
5:40 PM TO 6:00 PM	GAMAMABS PHARMA S.A. LEVEL 1, RECTOR GILLIS <a href="#">View company profile</a>	PCI BIOTECH HOLDING ASA (OSE:PCIB) LEVEL 2+, OUDE INFIRMERIE <a href="#">View company profile</a>	CURETIS N.V. LEVEL 1+, PRIORZAAL <a href="#">View company profile</a>
6:00 PM TO 6:20 PM	HEIDELBERG PHARMA AG LEVEL 1+, PRIORZAAL <a href="#">View company profile</a>	ACACIA PHARMA GROUP PLC LEVEL 2+, OUDE INFIRMERIE <a href="#">View company profile</a>	
6:30 PM TO 7:00 PM	WALK TO EVENING RECEPTION		
7:00 PM TO 10:30 PM	EVENING RECEPTION AND ENTERTAINMENT		
	Feestzalen Oude Vismijn Sint-Veerleplein 5, Ghent		

WEDNESDAY, MAY 16, 2018

8:00 AM	REGISTRATION OPENS HET PAND, GHENT
9:00 AM TO 10:10 AM	PRE-SEED SHOWCASE 2 LEVEL 2, ZAAL RECTOR VERMEYLEN Selected Pre-Seed Companies present to a diverse panel of <i>BioEquity Europe</i> 'judges' who provide high level feedback on their

business plan, presentation and overall strategy.

Moderator: Eric Pierce, Publisher, BioCentury

Judges:

- Sean Cao, Ph.D., Managing Director, C-Bridge Capital
- Emmanuelle Coutanceau, Ph.D. Partner, Novo Seeds
- Emmanuel Lacroix, Ph.D. Senior Director, Venture Investments, UCB Ventures
- Vanessa Malier, Managing Partner, Kurma Partners

Pre-Seed Companies:

- ADCendo Aps (9:00)
- Roscue (9:15)
- Abarceo Pharma AB (9:30)
- Polyneuron Pharmaceuticals (9:45)

9:00 AM TO 9:20 AM

AFFIMED N.V. (NASDAQ:AFMD)

LEVEL 1+, PRIORZAAL

[View company profile](#)

9:00 AM TO 9:10 AM

INTERNA TECHNOLOGIES B.V.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

9:10 AM TO 9:20 AM

STORM THERAPEUTICS LTD.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

9:20 AM TO 9:30 AM

REJUVENATE BIOMED NV

LEVEL 1, RECTOR GILLIS

View company profile

9:20 AM TO 9:40 AM

PROBIODRUG AG (EURONEXT:PBD)

LEVEL 1+, PRIORZAAL

View company profile

9:30 AM TO 9:40 AM

SOFTHALE N.V.

LEVEL 1, RECTOR GILLIS

View company profile

9:40 AM TO 9:50 AM

BIOGNOSYS AG

LEVEL 1, RECTOR GILLIS

View company profile

9:40 AM TO 10:00 AM

REALM THERAPEUTICS PLC  
(LSE:RLM)

LEVEL 1+, PRIORZAAL

View company profile

ORYZON GENOMICS S.A.

LEVEL 2+, OUDE INFIRMERIE

View company profile

9:50 AM TO 10:00 AM

REWIND THERAPEUTICS

LEVEL 1, RECTOR GILLIS

View company profile

10:00 AM TO 10:10 AM

GAMMADELTA THERAPEUTICS LTD.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

10:00 AM TO 10:20 AM

BEYONDSRING INC.  
(NASDAQ:BYSI)

ASCENEURON S.A.

LEVEL 1+, PRIORZAAL

LEVEL 2+, OUDE INFIRMERIE

[View company profile](#)

[View company profile](#)

10:10 AM TO 10:20 AM

OCTIMET ONCOLOGY NV

LEVEL 1, RECTOR GILLIS

[View company profile](#)

10:20 AM TO 11:20 AM

BIOTECH BUILDING BLOCKS PANEL - HOW TO GO FROM SERIES B TO BELLWETHER

LEVEL 2, ZAAL RECTOR VERMEYLEN

What C-level teams of European private biotechs need to put in place to become the next bellwether. This panel will discuss and debate what management teams of private companies need to put in place from shareholder and board level communications to control of assets and partnering.

Moderator: Jan De Kerpel Ph.D, Managing Director, Kempen & Co.

Speakers:

- Joe Anderson Ph.D., CEO, Arix Bioscience
- Gil Beyen, Chairman & CEO, Erytech Pharma
- Ulrich Dauer Ph.D., CEO, Probiodrug AG
- Arthur Franken, Partner, Gilde
- Marina Udier Ph.D, COO, Nouscom AG

10:20 AM TO 10:40 AM

ITEOS THERAPEUTICS S.A.

IMMUNICUM AB (SSE:IMMU)

LEVEL 1+, PRIORZAAL

LEVEL 2+, OUDE INFIRMERIE

[View company profile](#)

[View company profile](#)



MIKRO BIYOSISTEMLER INC.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

10:40 AM TO 11:00 AM

COMPLIX N.V.

OXTHERA AB

LEVEL 1+, PRIORZAAL

LEVEL 2+, OUDE INFIRMERIE

[View company profile](#)

[View company profile](#)

10:40 AM TO 10:50 AM

ABILITY PHARMACEUTICALS S.L.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

10:50 AM TO 11:00 AM

CONFO THERAPEUTICS N.V.

LEVEL 1, RECTOR GILLIS

[View company profile](#)

11:00 AM TO 11:20 AM

SORRENTO THERAPEUTICS  
(NASDAQ:SRNE)

BIOCLIN THERAPEUTICS INC.

LEVEL 1+, PRIORZAAL

LEVEL 2+, OUDE INFIRMERIE

[View company profile](#)

[View company profile](#)

11:20 AM TO 12:20 PM

NEW PATHWAYS FOR FINANCING EU STARTUPS

LEVEL 2, ZAAL RECTOR VERMEYLEN

Where early stage investors are playing in Europe what that could mean for your next fundraising round. Also how are investors prioritizing investment in brick and mortar companies versus more

virtual models and spin-outs of deprioritized assets from Big Pharma?

Moderator: Christina Takke Ph.D, Managing Partner, V-Bio Ventures

- Jeanne Bolger, Ph.D, Vice President, Venture Investments, Johnson & Johnson Development Corp.
- Johan Cardoen, Ph.D, Managing Director, VIB
- Hakan Goker, Ph.D., Senior Investment Director, M Ventures
- Frank Kalkbrenner, Ph.D, Head, Boehringer Ingelheim Venture Fund
- Vanessa Malier, Managing Partner, Kurma Partners
- Erica Whittaker, Ph.D, Head of UCB Ventures

11:20 AM TO 11:40 AM	REMYND N.V.	PSIOXUS THERAPEUTICS LTD.
	LEVEL 2+, OUDE INFIRMERIE	LEVEL 1+, PRIORZAAL
	<a href="#">View company profile</a>	<a href="#">View company profile</a>
11:40 AM TO 12:00 PM	AFFIBODY AB	SYNAFFIX B.V.
	LEVEL 1+, PRIORZAAL	LEVEL 2+, OUDE INFIRMERIE
	<a href="#">View company profile</a>	<a href="#">View company profile</a>
12:00 PM TO 2:00 PM	LUNCH AND NETWORKING TIME	
	LEVEL 0, KAPITELZAAL AND LEVEL 1	
12:00 PM TO 12:20 PM	ERYTECH PHARMA S.A. (NASDAQ:ERYP)	NOXXON PHARMA N.V. (EURONEXT:ALNOX)
	LEVEL 1+, PRIORZAAL	LEVEL 2+, OUDE INFIRMERIE
	<a href="#">View company profile</a>	<a href="#">View company profile</a>
12:20 PM TO 12:40 PM	BONE THERAPEUTICS S.A. (EURONEXT:BOTHE)	SANIONA AB (SSE:SANION)
		LEVEL 2+, OUDE INFIRMERIE

LEVEL 1+, PRIORZAAL

[View company profile](#)

[View company profile](#)

2:00 PM TO 3:20 PM

REGIONAL HOST SESSION

LEVEL 2, ZAAL RECTOR VERMEYLEN

### Belgian Pitch Session

- Gert Vanhees, Partner, Deloitte
- Elke Janssens, Partner, Nautadutilh
- Willem Broekaert, PhD, Managing Partner, V-Bio Ventures
- Jan Van den Bossche, Partner, Fund+
- Griet Van Poucke, PhD, Manager New Ventures, VIB
- Nico Vandervelpen, Managing Partner, BioQube Ventures
- Sylvie Ponchaut, PhD, Managing Director, BioWin
- Katya Smirnyagina, PhD, Partner, Capricorn Venture Partners

### Companies:

- AgomAb Therapeutics
- Apha.bio
- Confo Therapeutics
- Ontoforce
- Universiteit Gent
- VIB
- Vipun Medical

2:00 PM TO 2:20 PM

CENTOGENE AG

HERANTIS PHARMA PLC

LEVEL 1+, PRIORZAAL

LEVEL 1, RECTOR GILLIS

[View company profile](#)

[View company details](#)

2:20 PM TO 2:40 PM

EXICURE INC.

TARGOVAX A/S

LEVEL 1, RECTOR GILLIS

LEVEL 1+, PRIORZAAL

[View company profile](#)

[View company profile](#)

2:40 PM TO 3:00 PM

CLOSING RECEPTION

(FOR NEXT DAY)

THANK YOU

